Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 199Rectal Neoplasms 106Colonic Neoplasms 78Stomach Neoplasms 64Pancreatic Neoplasms 56Neoplasm Metastasis 50Esophageal Neoplasms 34Neoplasms 25Lymphoma 24Leukemia 24Adenocarcinoma Of Esophagus 22Burkitt Lymphoma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Carcinoma, Hepatocellular 16Cholangiocarcinoma 15Adenocarcinoma 15Biliary Tract Neoplasms 12Gallbladder Neoplasms 9Bile Duct Neoplasms 8Lymphoma, Mantle-Cell 7Colorectal Cancer Metastatic 7Osteosarcoma 6Esophageal Squamous Cell Carcinoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Liver Neoplasms 5Dendritic Cell Sarcoma, Interdigitating 5Breast Neoplasms 5Sarcoma 4Peritoneal Neoplasms 4

Interventions

Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × mCRC × Leucovorin × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡